Very interesting. Assuming we eliminated everything but accidental causes looks like we should live to about 120+ years. I think Sinclair had said that was the expected lifespan as well.
Taking the tool at face value, it seem that both personally and socially effort focused on circulatory diseases should give the biggest bang for the buck. Then again I didn’t run through different cases of combination so...
If the actuarial statistics I’ve read are accurate, about 1 in 1000 18 year old men in the US die before their 19th birthday. If the chance of dying each year stayed perfectly flat, life expectancy would be about 1000 years...
True, circulatory diseases would be a big win, but do you think the marginal buck there is likely to do as much as a marginal buck focused on aging giving the amount of funding allocated to each? If we add the R&D budgets focused on circulatory diseases to the treatment cost of circulatory diseases (potential profit pool for pharma companies), my intuition says that the number would be ~20-100x the total amount of funding to aging-stopping or -reversing technology. What do you think the ratio would be?
Very interesting. Assuming we eliminated everything but accidental causes looks like we should live to about 120+ years. I think Sinclair had said that was the expected lifespan as well.
Taking the tool at face value, it seem that both personally and socially effort focused on circulatory diseases should give the biggest bang for the buck. Then again I didn’t run through different cases of combination so...
If the actuarial statistics I’ve read are accurate, about 1 in 1000 18 year old men in the US die before their 19th birthday. If the chance of dying each year stayed perfectly flat, life expectancy would be about 1000 years...
Some have calculated lifespan would be 2800-8900 years on average without aging.
https://www.iii.org/fact-statistic/facts-statistics-mortality-riskhttps://math.stackexchange.com/questions/3044194/whats-the-average-life-expectancy-if-only-dying-from-accidents
True, circulatory diseases would be a big win, but do you think the marginal buck there is likely to do as much as a marginal buck focused on aging giving the amount of funding allocated to each? If we add the R&D budgets focused on circulatory diseases to the treatment cost of circulatory diseases (potential profit pool for pharma companies), my intuition says that the number would be ~20-100x the total amount of funding to aging-stopping or -reversing technology. What do you think the ratio would be?